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Abstract
Synovial fibroblasts in persistent inflammatory arthritis have been suggested to have paral-
lels with cancer growth and wound healing, both of which involve a stereotypical serum re-
sponse programme. We tested the hypothesis that a serum response programme can be
used to classify diseased tissues, and investigated the serum response programme in fibro-
blasts from multiple anatomical sites and two diseases. To test our hypothesis we utilized a
bioinformatics approach to explore a publicly available microarray dataset including rheu-
matoid arthritis (RA), osteoarthritis (OA) and normal synovial tissue, then extended those
findings in a new microarray dataset representing matched synovial, bone marrow and skin
fibroblasts cultured from RA and OA patients undergoing arthroplasty. The classical fibro-
blast serum response programme discretely classified RA, OA and normal synovial tissues.
Analysis of low and high serum treated fibroblast microarray data revealed a hierarchy of
control, with anatomical site the most powerful classifier followed by response to serum and
then disease. In contrast to skin and bone marrow fibroblasts, exposure of synovial fibro-
blasts to serum led to convergence of RA and OA expression profiles. Pathway analysis re-
vealed three inter-linked gene networks characterising OA synovial fibroblasts: Cell
remodelling through insulin-like growth factors, differentiation and angiogenesis through _3
integrin, and regulation of apoptosis through CD44. We have demonstrated that Fibroblast
serum response signatures define disease at the tissue level, and that an OA specific,
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serum dependent repression of genes involved in cell adhesion, extracellular matrix remod-
elling and apoptosis is a critical discriminator between cultured OA and RA
synovial fibroblasts.
Introduction
Determining the mechanisms underlying persistence of disease in arthritis remains a signifi-
cant challenge. The fibroblast-like synoviocyte (FLS) has become prominent as a mediator of
disease persistence, supported by the persistent in vitro phenotype of these cells exemplified by
the severe combined immunodeficiency (SCID) mouse model of cartilage invasion [1]. Osteo-
arthritis (OA) synovial fibroblasts have been investigated less extensively. Although OA FLS
show some degree of hyperplasia [2, 3], they do not possess significant invasive properties.
Transcriptomic analyses in conditions of high serum have revealed unique functional group-
ings of activated genes [4]. Such apparently imprinted characteristics are not unique amongst
fibroblasts. Chang et al demonstrated retained fibroblast regional memory after in vitro culture
[5]. However, this group also demonstrated a canonical serum response programme (CSR) in
fibroblasts exposed to high (10% fetal calf serum (FCS)) compared to very low (0.1% FCS)
serum [6, 7]. The presence of the CSR in publicly available gene expression profiles of cancer
tissues robustly predicted metastasis and poor survival [7]. Further parallels exist between inva-
sive tumours, wound healing and FLS. These include the expression of tumour associated
markers such as Fibroblast activation protein (FAP) [8], Galectin-3 [9] and S100A4 (FSP-1)
[10], evidence of distant spread of pathologically involved cells [11], and activation of pathways
implicated in wound healing such as TGFβmediated myofibroblast differentiation as shown
by Kasperkovitz et al [12]. The findings of Chang and Kasperkovitz [12] illustrate the potential
of microarray analysis to generate hypotheses about the mechanisms underlying tissue micro-
environments, but also highlight the critical effects of both anatomical site and serum exposure
upon transcriptomic profiles. No study has attempted to examine diseased synovial fibroblasts
in the context of serum stimulation. In order to fully understand the impact of serum in dis-
ease, we analysed transcriptional responses to serum of fibroblasts derived from three matched
anatomical locations in populations of RA and OA patients. We identified a strict hierarchy of
transcriptional regulation, and an OA synovium-specific signature, which is repressed in re-
sponse to serum stimulation and represents important regulatory pathways involving control
of extracellular matrix remodelling and apoptosis.
Results
A canonical fibroblast serum response signature discriminates between
normal, RA and OA synovial tissues
RA FALS display an agressive phenotype, which involves increased invasiveness and resistance
to apoptosis [13]. Because of this, the expansive synovial tissue called ‘pannus’ at the cartilage-
bone interface has been suggested to share many hallmarks of cancer. However, there is no evi-
dence of increased cell proliferation in RA compared to normal and OA FLS. Invasiveness, ap-
optosis and proliferation in RA FLS derived from patients share the same properties than their
in vivo counterparts [1]. We therefore formulated the hypothesis that a fibroblast serum-re-
sponse signature, linked to cancer clinical outcome, may be able to discriminate RA and OA
derived synovial fibroblasts. Consistent with the current understanding of the biology of
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synovial FLS, we also hypothesize that migration and cell death but not proliferation may be
the key difference between RA and OA derived FLS. We first tested this hypothesis by develop-
ing a statistical model predictive of disease type based on the original transcriptional signature
developed by Chang et al [6]. We were able to map 95% of the genes originally described on a
public domain dataset representing whole synovial tissue from normal, RA and OA individuals
[14]. The hypothesis was indeed consistent with the prediction results as a K-nearest neighbour
(KNN) based model was able to predict disease state with good accuracy. Normal samples were
predicted with a sensitivity of 61% and a specificity of 95%. RA samples were predicted with a
sensitivity of 88% and a specificity of 89% and OA samples were predicted with a sensitivity of
80% and a specificity of 81% (S1 Fig.). This observation therefore supported our hypothesis
that fibroblast pathways involved in wound healing and neoplasia are relevant to the persis-
tence of inflammation in RA and OA.
A distinct hierarchy of anatomical site and serum response distinguishes
fibroblasts derived from arthritis patients
Since the ‘core serum response’ signature (CSR) developed by Chang et al was based on fibro-
blasts derived from normal skin, lung and gum we reasoned that it may not fully represent the
responses of synovial fibroblast populations in diseased joints. We therefore set out to experi-
mentally define a serum response signature based on fibroblasts derived from both RA and OA
patients. In order to take account of the documented effect of site on fibroblast transcriptional
profiles and to address the possibility of multiple site involvement in systemic disease, we com-
pared the serum response of fibroblasts of synovial origin to those of bone marrow and skin
from the same individual. We set out to identify differentially expressed genes in at least one of
the fibroblast groups. By using a SAMmulticlass approach we could identify a signature of
3633 genes (FDR< 3% followed by a two-fold cut-off). Microarray gene expression was corre-
lated with qPCR data for validation purposes (S2 Table). Principal component analysis (PCA)
was used to visualise the relationship between the genes (Fig. 1). This unsupervised analysis
showed that fibroblasts cluster primarily on the basis of anatomical location. Furthermore all
matched low and high serum samples were separated on the first principal component (PC1,
x-axis). By contrast, minimal clustering on the basis of disease was seen. These results provide
the first evidence of a molecular hierarchy of transcriptional control, where site of origin is the
dominant factor, followed by response to serum stimulation and disease status.
Within anatomical locations, RA and OA fibroblasts are molecularly
distinct and differ in their response to serum stimulation
While the PCA described above provides initial evidence for the existence of a molecular hier-
archy of transcriptional control, it does not quantify the effect and it does not identify the spe-
cific genes linked to anatomical location, serum response and disease type. We therefore set
out to directly quantify the differences in gene expression across all three levels of organisation
and performed the following direct comparisons:
1. Anatomical location (Bone Marrow vs. Skin vs. Synovial tissue)
2. Serum Response (High vs. Low Serum)
3. Disease type (RA vs. OA)
Fig. 2A summarized the results of this analysis showing that as expected anatomical location
has the highest number of differentially expressed genes followed by serum response and finally
disease (3763, 435 and 180 differentially expressed genes, respectively at< 5% and a 2-fold cut-
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off). We then focused within each anatomical location and performed a more detailed analysis.
More precisely, within each tissue and within each disease group we identified genes differential-
ly expressed between low and high serum (Fig. 2B). We found that in both RA and OA the syno-
vial tissue has the highest number of differentially expressed genes (738 and 1419 genes
respectively). Bone marrow tissues both expressed similar number of genes (RA: 469, OA: 558)
while skin showed a much higher number of genes in RA (633) than OA (276) (Fig. 2B). We
then identified within each anatomical location and within each serum level the number of dif-
ferentially expressed genes between RA and OA samples (Fig. 2C). Here interestingly a large dif-
ference in the low serum but not the high serum condition could be observed in the synovial
tissue (302 vs. 0 differentially expressed genes respectively). Skin as well as bone marrow both
expressed similar numbers of differentially expressed genes (96±2) (Fig. 2C). The fold changes
of differentially expressed genes were broadly similar between groups indicating that numbers
Fig 1. Identification of a hierarchy of molecular signatures in arthritis derived fibroblasts. The relative similarity of the different groups of fibroblast in a
principal component (PC) plot is shown. Groups defined by disease state and anatomical location are indicated by coloured symbols whereas individual
samples response to serum (Hi, High serum; Lo, low serum) is shown by a solid grey line. The PCA clearly separates synovium (Syn, red and orange) from
bone marrow (BoM, blue and grey) and skin (Skn, green and light blue) on the first PC. Skin and bone marrow samples are only separated on the second PC.
Additionally it can be observed that all samples are separated by their serum response mainly on the first PC.
doi:10.1371/journal.pone.0120917.g001
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of genes are a useful approximation of the degree of difference observed between transcriptional
profiles. For each anatomical location we also performed a multi-class SAM analysis to identify
genes that change in at least one of the different serum and disease types. We then visualised the
resulting gene-lists using a PCA (Fig. 3). This clearly demonstrated that bone marrow and skin
RA and OA fibroblasts responded to serum following parallel trajectories along the first princi-
pal component (PC) and were separated by disease predominantly according to the second PC
(Figs. 3A and 3B), while RA and OA synovium fibroblasts separated along the second PC but
converged in response to serum (Fig. 3C). In order to investigate the serum response overlap be-
tween bone marrow and skin fibroblasts, we extracted the most contributing genes within the
first principle component, and found that 120 and 285 genes contributed to the first principle
component of bone marrow and skin PCA analyses respectively, sharing 36 genes. This exclu-
sive skin/bone marrow overlap suggested a specific synovial serum response.
Serum response signatures defined by anatomical location and disease
type define distinct functional profiles
Having defined the serum response signatures in each anatomical location and within each dis-
ease group we asked whether the serum response programs overlap significantly Samples de-
rived from all three different anatomical locations of RA patients exhibited a greater overlap in
serum response profile than OA samples, which exhibited more divergent, site-specific serum
responses (11% vs 3% in common, supplementary S2 Fig.). Next, in order to address the bio-
logical significance of our findings we used the downstream effect analysis pipeline within the
Fig 2. Differential gene expression analyses at tissue, serum and disease level. The figure shows the differential gene expression analysis performed
within each level of the study. For each level of organisation we quantified the number of differentially expressed genes at an FDR< 5% followed by a 2-fold
filter. This allowed us to devise a hierarchy of organisation that follows Anatomical Location then serum response and finally disease status (A). A more
detailed tissue-by-tissue analysis to identify serum response genes in RA and OA fibroblasts (B) and to identify disease genes within high and low serum (C)
was then performed. The arrows in panel A represent the direction of the hierarchy defined by the number of genes differentially expressed. BoM,
Bone marrow.
doi:10.1371/journal.pone.0120917.g002
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Fig 3. Serum response in arthritis derived fibroblasts within anatomical sites. The figure describes the
relationships between RA and OA derived fibroblasts in low and high serum conditions using PCA. Bone
marrow (A), skin (B) and synovium (C) derived fibroblasts are represented separately.
doi:10.1371/journal.pone.0120917.g003
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Ingenuity Pathway Analysis (IPA) knowledge management system. This algorithm assesses the
probability that the observed transcriptional response is consistent with a phenotypic change.
The rationale behind this approach is as follows: The IPA database contains experimentally ob-
served causal relationships that provide a direction of effect between genes and functional
terms. Given that generally a number of genes may be linked to any given function, a statistical
approach to quantify this effect was developed by the IPA Team. Functional terms that have
significantly more “increased” or “decreased” predictions are found by comparing the submit-
ted gene lists with a random selection with equal probability. Fig. 4 represents a summary of
the resulting functional terms linked to the serum response of anatomical locations and disease
types. Most of the genes submitted by each comparison can be classified into functions relating
to migration and invasion of tumor cell lines, proliferation of cells and cell viability (See S3
Table for more details). However there are a number functions specific to each anatomical site
and disease type. Particularly bone marrow and synovial tissue show a number of overlapping
functional terms such as invasion, synthesis of DNA and apoptosis. Moreover, bone marrow
RA specific functions are one of the largest set of functions associated to a number of genes
(423 genes associated to 30 increased and 104 genes to decreased functions) including differen-
tiation, angiogenesis, vasculogenesis, activation of tumor cell lines and apoptosis of tumor cell
lines (decreased). Within the synovial tissue, RA samples are characterized by proliferation of
fibroblasts, adhesion of tumor cell lines and necrosis and cell death (decreased 145 genes in 2
functions). Similarly to RA, OA also regulate genes associated with apoptosis but with a much
larger number of genes (246 genes associated to 2 functions). Interestingly, OA synovial sam-
ples are the only sample type with functions relating to sensitization of cells which may have an
impact on their ability to respond to serum.
Analysis of the synovium fibroblast response to serum identifies
OA-specific repression of a tissue remodelling transcriptional signature
A key question in arhritis research is whether RA and OA fibroblasts are different in their abili-
ty to respond to grow-factor signals. As shown in Fig. 3C, the transcriptional state of RA and
OA derived fibroblasts converged in high serum culture conditions. We therefore set out to fur-
ther characterize the difference in response between RA and OA in low serum conditions with-
in the synovium and to assess whether these changes in expression follow serum stimulation.
In the low serum condition, 302 genes were differentially expressed between synovial OA and
RA fibroblasts. Genes significantly down-regulated in OA synovial fibroblasts during low to
high serum transition and not included in classical GO classifiers included tumour suppressor
and pro-apoptotic genes PTEN, SLIT3, TRERF1 (TReP-132), SHOX, SH3D19, ubr5 and EDD;
genes with roles in cytoskeletal rearrangement supervillin, paxillin, and genes involved in ubi-
quitination and signalling included PIAS1, crebbp and the IGFBP family of genes. Genes regu-
lated at higher levels in RA than OA fibroblasts included Secretogranin-II and tensin 3. Of the
302 genes, 98% were not differentially expressed in bone marrow or skin fibroblasts, confirm-
ing a synovium-specific response (Fig. 5A). Fig. 5B shows the relative expression in low and
high serum of differentially expressed genes in synovial fibroblasts. The majority of genes
(88%) were down-regulated in response to high serum in OA synovial fibroblasts. This rela-
tionship was also seen to a lesser extent in skin and bone marrow OA fibroblasts, while RA fi-
broblasts showed no convincing regulation of this gene list in response to serum. To define the
biological relevance of the serum mediated synovium-specific disease signature, we performed
a network analysis using Ingenuity Pathway Analysis software. This identified three inter-
linked gene networks representing the control of actin remodelling through insulin-like growth
factor associated proteins (IGFBP5, IGFBP6, IGFBP7 and GnRH1) (Fig. 6A), control of tissue
Profiling Stromal Cells Reveal Site, Serum Response and Disease Type
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Fig 4. Functional classification of differentially expressed genes. Each set of differentially expressed genes in response to serum was submitted to
Ingenuity and searched for functional terms with predicted increased (red) or decreased (green) activity.
doi:10.1371/journal.pone.0120917.g004
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remodelling by β3 integrin (Fig. 6B), and regulation of apoptosis through CD44 (Fig. 6C), each
representing facets of the fibroblast phenotype in OA. This last observation shows that molecu-
lar signatures characterizing RA fibroblast serum response not only discriminate between RA
and OA FLS but that the functional profile is related primarily to adhesion and migration path-
ways. This is consistent with our initial hypothesis.
Discussion
We hypothesised that the CSR of Chang et al would differentiate persistent inflammatory RA
from OA and normal synovium, and showed this to be the case at the tissue level. This observa-
tion places inflammatory arthritis at the centre of the long-standing debate regarding the rela-
tionship between wound healing, cancer and persistent inflammation [15]. Comparison of
serum responses across site and disease led to the discovery of a hierarchy of transcriptomic
Fig 5. A synovium specific gene signature in low serum. Panel A shows a Venn diagram showing the overlap between genes differentially expressed in
synovium, bone marrow and skin derived fibroblasts between RA and OA groups in the low serum state. The high degree of overlap between skin and bone
marrow and the very different signature in the synovium are evident. Panel B shows the result of a two factor cluster analysis of the 296 synovium specific
genes identified in Panel A. Panel C represents the number of statistically differentially expressed genes between low and high serum states within each
tissue and disease. As expected OA synovium is associated with the largest number of differentially expressed genes.
doi:10.1371/journal.pone.0120917.g005
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Fig 6. Ingenuity Network analyses. The three major networks identified were: (A) Actin cytoskeleton
remodelling by extracellular insulin-like growth factor binding proteins through gonadotropic hormones. (B)
ITGB3 signalling connected to differentiation and angiogenesis. (C) Regulation of apoptosis through CD44.
Yellow nodes represent genes resulting from input whereas empty nodes represent added genes by
Ingenuity. Dashed and solid lines represent indirect and direct relationships respectively.
doi:10.1371/journal.pone.0120917.g006
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signatures. The primacy of site as the strongest determinant of transcriptional fibroblast re-
sponse fits with both Chang et al’s findings and clinical observations of organ specific disease
[16]. Within anatomical sites, skin and bone marrow fibroblasts exhibited parallel serum re-
sponses regardless of disease. However the serum responses of RA fibroblasts exhibited greater
overlap than OA fibroblasts and were broadly functionally aligned. This alignment of serum re-
sponses in RA could result from exposure to a systemic cytokine milieu, or from a field effect
in mesenchymal precursors residing in bone marrow or local niches. Intriguingly, cultured
skin and bone marrow fibroblasts also retained a robust transcriptional memory of disease fol-
lowing in vitro culture analogous to the disease memory exhibited by RA fibroblasts in the
SCID mouse invasiveness model [1]. This is highly suggestive of underlying epigenetic mecha-
nisms, just as site specific gene expression results from noncoding RNA (HOTAIR—a 2.2kb
ncRNA fragment in the HOXC locus) driven epigenetic regulation of developmentally express-
ed genes [17]. We have previously shown that transcriptional profiles in lymphoid and periph-
eral fibroblasts may be modified under the influence of cytokine treatment [16]. The
phenotype of all fibroblasts in RA may therefore result from in vivo modification of the serum
response programme under the influence of persistent cytokine exposure. This finding has
wider implications, not least for mesenchymal stem cell therapy, where allogeneic rather than
autologous therapy may be more effective. Small numbers of genes linking fibroblast behaviour
in RA and cancer have been previously identified [18]; our novel approach identified links to
additional genes that are relatively silenced in RA compared to OA fibroblasts. An example is
the tumour suppressor PTEN, the low expression of which at sites of synovial invasion and
growth has been described by Pap et al. [19] SLIT3 specifically, along with other SLIT/ROBO
family members, is inactivated by promoter hypermethylation in multiple human cancers [20],
and antagonizes invasiveness of RA synovial fibroblasts [21]. SH3D19 codes for the tumour
suppressor EBP that inhibits ras driven transformation in acute myeloid leukaemia [22]. ubr5
(EDD), a ubiquitin ligase, similarly acts as a DNA damage checkpoint with under-expression
leading to cell cycle activation [23]. Responsiveness of these pathways in OA may help to ex-
plain the different clinical and radiological phenotypes seen in OA and invasive RA. Ingenuity
pathway analysis identified three inter-linked gene networks: The first network represents the
insulin-like growth factor signalling network. Transcription of the IGFBP family of genes
which mediate profibrotic and migratory changes [24] has been described in a “low inflamma-
tion” group of RA fibroblasts by Kasperkovitz et al [12] and by Seki et al using differential sub-
traction techniques [25]. The second network represents the interaction between β3 integrin
(ITGB3) and matrix components with signalling to differentiation and angiogenesis pathways.
ITGB3 binds to multiple extracellular matrix components and growth factors including plate-
let-derived growth factor (PDGF), Collagens and Fibulin 2 [26–29]. Treatment of cells with
PDGF-BB has been shown to increase the expression of ITGB3 [30] as well as increase recruit-
ment of ITGB3 to the cell surface [28]. ITGB3:PTPN11 complexes also inhibit dephosphoryla-
tion of insulin-like growth factor-I receptor (IGF-IR), leading to inhibition of apoptosis via Akt
and BclXL; hence decreased ITGB3 expression promotes apoptosis [31]. Angiogenesis related
genes were consistently identified in RA fibroblast serum responses. However, although identi-
fied as a potential target in RA, an αvβ3 monoclonal antibody (Vitaxin) was withdrawn after
trials failed to show therapeutic benefit [32]. Furthermore, β3 and αvβ3 integrin knockout
mice exhibit enhanced pathological angiogenesis of implanted tumours while ITGB3 over-ex-
pressing models demonstrate small new vessels deficient in pericytes [33, 34]. The role of αvβ3
integrins in angiogenesis therefore remains controversial. The CD44 pathway covers a broad
spectrum of genes, including the MAPKinases and PI3Kinase that are all implicated in control
of apoptosis and survival [35, 36]. Furthermore FOXC1 and CYCS are regulators of apoptosis,
highlighted by gene ontology analysis as the most enriched term in this pathway. Our
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investigations shed light on the findings of Del Rey et al [4] who compared transcriptional pro-
files of synovial fibroblasts in high serum. They were surprised at the small number of differen-
tially expressed genes seen, an explanation for which is provided by the serum conditions in
which their experiments were conducted. Intriguingly, both studies identified unique aspects
of the osteoarthritis synovial fibroblast phenotype, including cell adhesion and motility factors,
and a conspicuous absence of proinflammatory cytokine pathways. We have demonstrated
that serum response programmes segregate both tissues and fibroblasts from different sites and
diseases. This may provide a molecular explanation for the ability of TGFβ linked pathways,
that form a part of this response, to sub-classify disease. These data also demonstrate at a tran-
scriptome level that low serum conditions will increase the likelihood of identifying disease-
specific signatures.
Materials and Methods
Analysis of synovial tissue datasets from public repository
We retrieved a dataset from the NCBI GEO database which contained synovial tissue biopsy
samples from RA, OA and normal patients (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE12021) [14]. The dataset was normalized using robust multi-array average (RMA)
methodology; genes with expression close to the detection level were removed. We mapped
cDNA common serum response (CSR) genes to Affymetrix1 Ids using the ID converter facility
in DAVID [37, 38]. Expression of successfully mapped genes was then determined in the
GSE12021 dataset. To determine the ability of the CSR to classify synovial tissue from different
diseases, tissue datasets were classified by CSR genes using a k-nearest neighbour (KNN) classi-
fication algorithm, with validation by a leave one out cross-validation (LOOCV) procedure.
Patients and fibroblast culture
Fibroblasts were isolated as previously described [39] from synovium, bone marrow and skin
tissue samples taken at the time of knee or hip replacement surgery from 12 rheumatoid arthri-
tis patients meeting the 1987 ACR criteria [40] and 6 osteoarthritis patients diagnosed on the
basis of characteristic x-ray findings and the absence of features suggestive of inflammatory ar-
thritis (S1 Table). Only one hip sample was present in either disease group. Fibroblasts were
maintained in fibroblast medium (consisting of 81.3% RPMI 1640, 10% FCS, 0.81x MEM non-
essential amino acids, 0.81 mM sodium orthopyruvate, 1.62 mM glutamine, 810 U/ml penicil-
lin and 81 μg/mL streptomycin) at 37°C in a humidified 5% CO2 atmosphere. Ethical approval
for the use of this material was given by the ‘NRES Committee West Midlands—The Black
Country’ and all patients gave written informed consent (LREC reference 5735). RA disease ac-
tivity was quantified using the DAS28 disease activity score [41].
RNA extraction and microarray hybridization
Cells were seeded in duplicate at the required density using 10% FCS. Once attached, the medi-
um was removed and the cells washed in serum free medium before replacing with fibroblast
medium, which was identical but contained either 10% or 0.1% FCS [6]. mRNA was extracted
from all fibroblasts at passage 5, under identical conditions. In order to remove confluence of
cells as a confounding factor, proliferation rates were measured, and appropriate numbers of
cells seeded to achieve 75% confluent cultures at harvest. Fibroblasts were retrieved from cul-
ture by trypsin digestion and washed in fibroblast medium then PBS before resuspending in
200 μl of RLT RNA protection buffer (Quiagen). 102 fibroblast samples in all were prepared ac-
cording to Affymetrix1manufacturer instructions using 50 ng total RNA, which was amplified
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using Nugen™ Ovation™ Biotin RNA Amplification prior to hybridization with U133 plus 2.0
Affymetrix1 Genechips. All chips passed QC criteria and visual inspection of Expressionist
thumbnail images. The data is available under GEO accession number GSE56409.
Array validation using quantitative PCR
Synovial fibroblasts from 3 OA and 3 RA patients were cultured as above. Cells were trypsi-
nised and RNA extraction performed using an RNeasy kit (Qiagen). RNA from 1×105 fibro-
blasts was reverse transcribed using Superscript Vilo (Life Technologies). 1 μl of the resulting
cDNA was added to the real-time PCR master mix (Applied Biosystems) and TaqMan prim-
ers/probes were used to measure the relative quantities of SLIT3, PIAS1 and TNS3 (VIC la-
belled) with GAPDH (FAM labelled) as control using an ABI 7900HT machine (Applied
Biosystems).
Dataset and data processing
Out of the 108 samples retrieved six samples did not meet quality control and hence did not
undergo further analysis. These included 1x Bone Marrow RA low serum, 1x Bone Marrow RA
high serum, 1x Skin OA low serum, 1x Synovial OA low serum, 1x Synovial OA high serum
and 1x Skin OA high serum sample. Gene expression data from the Affymetrix1 arrays were
processed and normalized using RMAmethodology. Data were processed to remove genes
with expression close to the detection level.
Identification of differentially expressed genes
Statistical analysis for microarrays (SAM) [42] as implemented by the R package (samr) was
used to identify differentially expressed genes between groups. A cut-off of FDR< 3% and an
additional cut-off of two fold change was applied on all differentially expressed gene sets. Ini-
tially we identified differentially expressed genes for each of the three levels of organisation
(anatomical location, serum response and disease type). Here all samples belong to the given
level were compared in either a “Multiclass” comparison (anatomical location) or a “Two class
unpaired” comparison (serum response and disease type) using the SAM algorithm. The num-
ber of differentially expressed genes were then filtered to the previously mentioned thresholds.
To identify genes differentially expressed in each tissue and within serum and disease types, we
first subset the data into the three tissues. Then for each serum level we identify differentially
expressed genes between RA and OA. Similarly for each disease type we identify differentially
expressed genes between high and low serum. Apparent discrepancies in total gene numbers in
tables compared to the text result from the common phenomenon of genes with multiple Affy-
metrix1 IDs (See S1 Dataset for more details).
K-nearest neighbour classification
To test whether the CSR signature is able to distinguish between normal, RA and OA samples
retrieved from the public domain we applied a K-nearest neighbour algorithm as implemented
by the knn.cv function in the ‘class’ library in the statistical environment R. This methodology
uses a leave-one-out-crossvalidation. For each sample in the training set the k nearest neigh-
bours are identified and the classification decided by majority vote. We have tested 2< k< 10
and observed that the accuracy was independent of the value of k (standard deviation of the
prediction accuracy over the values of k was< 0.05% in all comparisons).
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Data reduction techniques
Genes differentially expressed between all sample groups were visualised using Principal com-
ponent analysis (PCA), a technique designed to represent highly multi-dimensional objects in
a lower dimensionality space (Fig. 2). The first principal component (PC) on the x-axis repre-
sents the majority of the variance information, whilst the second PC on the y-axis, is orthogo-
nal to the first PC and holds less variance. All data were mean centred prior to application of
PCA using the prcomp function in the statistical environment R [43].
Ingenuity Pathway Analysis (IPA) of differentially expressed gene sets
Gene sets derived from differential gene expression and Venn diagram analyses were analysed
using the IPA application (Palo Alto, http://www.ingenuity.com) that uses the Ingenuity Path-
ways Knowledge Base (IPKB) to explore biological interaction networks. Each gene identifier is
mapped to a global molecular network within IPKB. An algorithm then generates networks
based on the connectivity of focus genes, limited to a maximum of 35 genes for simpler visuali-
sation. For the downstream effect analysis gene lists and calculated fold changes were uploaded
to the IPKB. For each biological function within the IPKB an activation z-score is calculated by
the software. Here the molecular network within IPKB is interrogated and experimentally ob-
served causal relationships between genes and function extracted. These connections provide a
literature-derived direction of effect which is used in combination with the foldchange to calcu-
late the activation state of the given functional terms. As multiple genes may be connected to a
function a statistical approach is necessary to calculate its significancy as compared to a ran-
domly derived variable. This variable is obtained by randomly choosing 1 or -1 with equal
probability representing an “increased” or “decreased” state respectively. For each number of
genes affecting the functional term the number of “increased” (N+) and “decreased” (N−) pre-
dictions is summed up for the random. This however assumes that there is only 1 possible
downstream effect to a given function. To correct for this the IPAKB uses a weighted z-score
statistics in which:
wi ¼
jMactivating Minhibiting j
Mactivating þMinhibiting þ 1
ð1Þ
whereMactivating andMinhibiting represent the number of ﬁndings underlying an edges “activa-
tion” or “inhibition” respectively. This is then used to correct for the direction of change within
the z score algorithm. The z-score can therefore be calculated as:
z ¼ x
sx
¼
P
iwixiﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
iw
2
i
p ð2Þ
Supporting Information
S1 Fig. Classification of normal and arthritis synovium biospies using a canonical serum
response signature. The figure shows the probability of a synovium biopsy sample to be cor-
rectly classified as normal, RA or OA on the basis of a canonical serum response signature. The
x axis represents each individual sample biopsy in the 3 groups and the y axis the probability of
correct classification estimated using a leave one out cross-validation (LOOCV) procedure.
The percentage of correct classification using a majority rule is indicated below the
sample labels.
(TIFF)
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S2 Fig. Venn diagram representing disease specific serum response. A) Shows the Venn dia-
gram for the response to serum in all tissues in OA. B) represents the serum response of all tis-
sues in RA patients.
(TIFF)
S1 Table. Patient demographic and disease data. RhF, rheumatoid factor; DMARD, Disease-
modifying antirheumatic drug; MTX, methotrexate, weekly dose; D-PEN, D-penicillamine;
Gold, intramuscular gold, monthly dose; AZA, azathioprine; SSA, sulphasalazine.
(DOCX)
S2 Table. Fold changes in gene expression in OA versus RA synovial fibroblasts in low
serum. Data were obtained from 3 synovial fibroblast lines. qPCR, quantitative PCR; PIAS1,
protein inhibitor of activated STAT-1 (signal transducer and activator of transcription-1).
(DOCX)
S3 Table. Functional associations in serum response. Overview of the Functional associa-
tions in the serum response between RA and OA fibroblasts within each anatomical site. The
numbers represent “number of genes increased”/“number of genes decreased” within
each term.
(DOCX)
S1 Dataset. Results from the differential gene expression analysis. An excel file containing
all results from the SAM analysis for all comparisons performed, including up and down regu-
lated genes with their associated Gene ID, Fold Change and q-value (%).
(XLSX)
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